{"pmid":32294817,"title":"[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019].","text":["[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019].","The rapid spread of the coronavirus disease 2019 (COVID-19) has become a global threat. But the pathogenesis and treatment of the disease are not clear yet. Virological researches revealed close relationship between 2019-nCoV and SARS-CoV. The experience and knowledge we gained from severe acute respiratory syndrome (SARS), especially with regard to the time course of viral replication, host immune response and clinical progression of the patient, may provide important insights into understanding and management of COVID-19. Clinical deterioration accompanied by decreasing viral load in the second week after symptom onset was noted both in SARS and COVID-19, suggesting that the lung damage at this phase is more related to excessive host immune response rather than uncontrolled viral replication.","Zhonghua Jie He He Hu Xi Za Zhi","Liu, Y J","Yang, Y L","Xu, Y","32294817"],"abstract":["The rapid spread of the coronavirus disease 2019 (COVID-19) has become a global threat. But the pathogenesis and treatment of the disease are not clear yet. Virological researches revealed close relationship between 2019-nCoV and SARS-CoV. The experience and knowledge we gained from severe acute respiratory syndrome (SARS), especially with regard to the time course of viral replication, host immune response and clinical progression of the patient, may provide important insights into understanding and management of COVID-19. Clinical deterioration accompanied by decreasing viral load in the second week after symptom onset was noted both in SARS and COVID-19, suggesting that the lung damage at this phase is more related to excessive host immune response rather than uncontrolled viral replication."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Liu, Y J","Yang, Y L","Xu, Y"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32294817","week":"202016|Apr 13 - Apr 19","doi":"10.3760/cma.j.cn112147-20200218-00119","keywords":["2019-nCoV","Chloroquine","Coronavirus disease 2019","Immune response","Lopinavir","SARS-CoV","Viral load"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664266651120435202,"score":8.233237,"similar":[{"pmid":32247050,"pmcid":"PMC7118633","title":"Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV.","text":["Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV.","BACKGROUND: The rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled 2019 novel coronavirus (2019-nCoV), has become a global threat. Awareness of the biological features of 2019-nCoV should be updated in time and needs to be comprehensively summarized to help optimize control measures and make therapeutic decisions. METHODS: Based on recently published literatures, official documents and selected up-to-date preprint studies, we reviewed the virology and origin, epidemiology, clinical manifestations, pathology and treatment of 2019-nCoV infection, in comparison with severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV) infection. RESULTS: The genome of 2019-nCoV partially resembled SARS-CoV and MERS-CoV, and indicating a bat origin. The COVID-19 generally had a high reproductive number, a long incubation period, a short serial interval and a low case fatality rate (much higher in patients with comorbidities) than SARS and MERS. Clinical presentation and pathology of COVID-19 greatly resembled SARS and MERS, with less upper respiratory and gastrointestinal symptoms, and more exudative lesions in post-mortems. Potential treatments included remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible). CONCLUSION: The initial experience from the current pandemic and lessons from the previous two pandemics can help improve future preparedness plans and combat disease progression.","Int J Infect Dis","Xie, Mingxuan","Chen, Qiong","32247050"],"abstract":["BACKGROUND: The rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled 2019 novel coronavirus (2019-nCoV), has become a global threat. Awareness of the biological features of 2019-nCoV should be updated in time and needs to be comprehensively summarized to help optimize control measures and make therapeutic decisions. METHODS: Based on recently published literatures, official documents and selected up-to-date preprint studies, we reviewed the virology and origin, epidemiology, clinical manifestations, pathology and treatment of 2019-nCoV infection, in comparison with severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV) infection. RESULTS: The genome of 2019-nCoV partially resembled SARS-CoV and MERS-CoV, and indicating a bat origin. The COVID-19 generally had a high reproductive number, a long incubation period, a short serial interval and a low case fatality rate (much higher in patients with comorbidities) than SARS and MERS. Clinical presentation and pathology of COVID-19 greatly resembled SARS and MERS, with less upper respiratory and gastrointestinal symptoms, and more exudative lesions in post-mortems. Potential treatments included remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible). CONCLUSION: The initial experience from the current pandemic and lessons from the previous two pandemics can help improve future preparedness plans and combat disease progression."],"journal":"Int J Infect Dis","authors":["Xie, Mingxuan","Chen, Qiong"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247050","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijid.2020.03.071","keywords":["2019-nCoV","COVID-19","MERS-CoV","SARS-CoV","SARS-CoV-2"],"source":"PubMed","topics":["Mechanism","Diagnosis","Treatment","Prevention"],"weight":1,"e_drugs":["tocilizumab","Chloroquine"],"_version_":1663352135814742016,"score":142.27664},{"pmid":32234130,"title":"[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","text":["[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.","Zhonghua Yu Fang Yi Xue Za Zhi","Shi, Y","Wang, N","Zou, Q M","32234130"],"abstract":["The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Shi, Y","Wang, N","Zou, Q M"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234130","week":"202014|Mar 30 - Apr 05","doi":"10.3760/cma.j.cn112150-20200317-00366","keywords":["2019-nCoV","Animal models","Vaccine"],"source":"PubMed","locations":["Moderna"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135484440576,"score":141.78043},{"pmid":32105090,"title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.","text":["Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.","As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.","Asian Pac J Allergy Immunol","Prompetchara, Eakachai","Ketloy, Chutitorn","Palaga, Tanapat","32105090"],"abstract":["As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future."],"journal":"Asian Pac J Allergy Immunol","authors":["Prompetchara, Eakachai","Ketloy, Chutitorn","Palaga, Tanapat"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105090","week":"20209|Feb 24 - Mar 01","doi":"10.12932/AP-200220-0772","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134436913153,"score":139.34601},{"pmid":32293710,"title":"Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.","text":["Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.","COVID-19 infection and its severity can be explained by the concentration of glycosylated SARS- CoV-2 viral particles in the lung epithelium, the concentration of glycosylated angiotensin converting enzyme receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8-10 after symptom onset, which may be related to both. Binding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease. It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV- 2 spike protein form at day 7-10, results in acute respiratory distress syndrome (ARDS) in susceptible patients. It is also allows consideration of agents, such as hydroxychloroquine, which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate the M1 to M2 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS. This article is protected by copyright. All rights reserved.","J Med Virol","Brufsky, Adam","32293710"],"abstract":["COVID-19 infection and its severity can be explained by the concentration of glycosylated SARS- CoV-2 viral particles in the lung epithelium, the concentration of glycosylated angiotensin converting enzyme receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8-10 after symptom onset, which may be related to both. Binding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease. It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV- 2 spike protein form at day 7-10, results in acute respiratory distress syndrome (ARDS) in susceptible patients. It is also allows consideration of agents, such as hydroxychloroquine, which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate the M1 to M2 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Brufsky, Adam"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293710","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25887","keywords":["SARS coronavirus","antibody-mediated cell-mediated cytotoxicity","antiviral agents"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Hydroxychloroquine"],"_version_":1664266295676239872,"score":139.03233},{"pmid":32235945,"title":"Virological assessment of hospitalized patients with COVID-2019.","text":["Virological assessment of hospitalized patients with COVID-2019.","Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 2019(1,2). Initial outbreaks in China involved 13.8% cases with severe, and 6.1% with critical courses(3). This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung(2,4). By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity, but also aided the control, of severe acute respiratory syndrome (SARS) in 2003(5). However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting the potential for pre- or oligosymptomatic transmission(6-8). There is an urgent need for information on body site-specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 x 10(8) RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples, in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat and lung samples from the same patient, proving independent replication. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (14 days in all), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts the prospects of COVID-19 containment in perspective.","Nature","Wolfel, Roman","Corman, Victor M","Guggemos, Wolfgang","Seilmaier, Michael","Zange, Sabine","Muller, Marcel A","Niemeyer, Daniela","Jones, Terry C","Vollmar, Patrick","Rothe, Camilla","Hoelscher, Michael","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Ehmann, Rosina","Zwirglmaier, Katrin","Drosten, Christian","Wendtner, Clemens","32235945"],"abstract":["Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 2019(1,2). Initial outbreaks in China involved 13.8% cases with severe, and 6.1% with critical courses(3). This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung(2,4). By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity, but also aided the control, of severe acute respiratory syndrome (SARS) in 2003(5). However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting the potential for pre- or oligosymptomatic transmission(6-8). There is an urgent need for information on body site-specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 x 10(8) RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples, in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat and lung samples from the same patient, proving independent replication. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (14 days in all), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts the prospects of COVID-19 containment in perspective."],"journal":"Nature","authors":["Wolfel, Roman","Corman, Victor M","Guggemos, Wolfgang","Seilmaier, Michael","Zange, Sabine","Muller, Marcel A","Niemeyer, Daniela","Jones, Terry C","Vollmar, Patrick","Rothe, Camilla","Hoelscher, Michael","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Ehmann, Rosina","Zwirglmaier, Katrin","Drosten, Christian","Wendtner, Clemens"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32235945","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41586-020-2196-x","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1663352135585103872,"score":134.7131}]}